Boston, MA 08/11/2014 (wallstreetpr) – Clovis Oncology Inc (NASDAQ:CLVS) posted second quarter financial results and gave the necessary information on its clinical developmental programs for the year. It said that the CO-1686 NDA submission is expected by mid-2015. President and CEO, Patrick J. Mahaffy said that the company is going through an exciting time. It […]
